blog.aids.gov − Clinical Trials
AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV - Changing to HIV.gov in Spring 2017

MENU

Clinical Trials

Historic HIV Vaccine Clinical Trial: Facebook Live with NIH’s Dr. Dieffenbach

Dr. Carl Dieffenbach on Facebook Live from Cape Town, South Africa

In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH’s Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV vaccine clinical trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental…

Watch HIV Vaccine Trial Launch in South Africa Via Facebook Live! This Wednesday!

niaid-fauci-quote-for-hvtn-702-blog-resized-nov-2016

Director’s Note, Office of HIV/AIDS and Infectious Disease Policy, HHS: Scientific advances have given us the tools we need to end new HIV infections and save lives. But our work is not yet done, either here in the U.S. or around the world. As we approach the observance of World AIDS Day on December 1…

First New HIV Vaccine Efficacy Study in Seven Years Has Begun

nih-logo-resized-nov-2016

South Africa Hosts Historic NIH-Supported Clinical Trial November 27, 2016 The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown…

ICYMI – Advances in Research on HIV Prevention for Women

carl-and-anne-fb-live-hivr4p-resized-oct-2016

Last week, in a Facebook Live event we heard from NIH’s Dr. Carl Dieffenbach about some new developments in HIV prevention for women shared at the HIV Research for Prevention Conference  (R4P) in Chicago.  Carl is the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases. He and his…

HIV Vaccine Research: Update from NIH’s Dr. Dieffenbach from 2nd Day of AIDS 2016

Carl day 2 FB Live resized

As the second day of the International AIDS Conference (AIDS 2016) came to a close in Durban, South Africa, we caught up with Dr. Carl Dieffenbach again via Facebook Live to get his thoughts on some of the day’s highlights. He is Director of the Division of AIDS at NIH’s National Institute of Allergy and…

Vaginal Ring May Cut HIV Infection Risk if Used Consistently

Vaginal ring - cropped July 2016

NIH Clinical Trial Will Clarify Relationship between Ring Adherence, HIV Infection Risk A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent. This finding is being reported today…

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25 A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by…

NIH’s Dr. Carl Dieffenbach Shares Highlights as IAS 2015 Begins

IAS2015 logo crop2

After the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) got underway in Vancouver, Canada yesterday, July 20, we spoke by Skype with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). He shared some highlights from the first full…